494.46
-11.32 (-2.24%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vertex Pharmaceuticals Incorpor | Bullish | Bullish |
Stockmoo Score
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Large Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 558.00 (Guggenheim, 12.85%) | Buy |
| Median | 500.00 (1.12%) | |
| Low | 376.00 (Canaccord Genuity, -23.96%) | Sell |
| Average | 497.73 (0.66%) | |
| Total | 8 Buy, 2 Hold, 1 Sell | |
| Avg. Price @ Call | 486.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 02 Aug 2024 | 480.00 (-2.92%) | Buy | 494.46 |
| 22 Jul 2024 | 480.00 (-2.92%) | Buy | 495.91 | |
| Guggenheim | 02 Aug 2024 | 558.00 (12.85%) | Buy | 494.46 |
| Piper Sandler | 02 Aug 2024 | 535.00 (8.20%) | Buy | 494.46 |
| Canaccord Genuity | 31 Jul 2024 | 376.00 (-23.96%) | Sell | 495.72 |
| TD Cowen | 23 Jul 2024 | 500.00 (1.12%) | Buy | 490.32 |
| HC Wainwright & Co. | 19 Jul 2024 | 500.00 (1.12%) | Buy | 491.57 |
| Morgan Stanley | 11 Jul 2024 | 455.00 (-7.98%) | Hold | 492.13 |
| Redburn Atlantic | 27 Jun 2024 | 545.00 (10.22%) | Buy | 472.51 |
| Wells Fargo | 24 Jun 2024 | 555.00 (12.24%) | Buy | 474.95 |
| Argus Research | 17 Jun 2024 | 550.00 (11.23%) | Buy | 473.69 |
| RBC Capital | 11 Jun 2024 | 421.00 (-14.86%) | Hold | 481.53 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |